FMP

FMP

Enter

PTCT - PTC Therapeutics, In...

photo-url-https://images.financialmodelingprep.com/symbol/PTCT.png

PTC Therapeutics, Inc.

PTCT

NASDAQ

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

54.5 USD

1.74 (3.19%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

1.86B

2.28B

2.45B

2.29B

2.51B

2.74B

3B

3.28B

3.59B

3.92B

Revenue %

-

22.94

7.43

-6.53

9.46

9.34

9.34

9.34

9.34

Ebitda

425.59M

581.86M

598.9M

-598.89M

575.55M

382.08M

417.75M

456.75M

499.4M

546.02M

Ebitda %

22.91

25.48

24.41

-26.12

22.93

13.92

13.92

13.92

13.92

Ebit

318.44M

419.94M

438.46M

-754M

420.32M

204.54M

223.64M

244.52M

267.35M

292.31M

Ebit %

17.14

18.39

17.87

-32.88

16.75

7.45

7.45

7.45

7.45

Depreciation

107.16M

161.92M

160.43M

155.1M

155.23M

177.54M

194.11M

212.23M

232.05M

253.71M

Depreciation %

5.77

7.09

6.54

6.76

6.18

6.47

6.47

6.47

6.47

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep